基于木犀草素的草药Unani制剂与呋喃妥因在无并发症尿路感染妇女中的随机比较研究。

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Arshiya Sultana, Khaleequr Rahman, Saiyad Shah Alam
{"title":"基于木犀草素的草药Unani制剂与呋喃妥因在无并发症尿路感染妇女中的随机比较研究。","authors":"Arshiya Sultana, Khaleequr Rahman, Saiyad Shah Alam","doi":"10.2174/0113816128389673250415101004","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Urinary tract infection (UTI) is a common infection, particularly among reproductive- age and elderly women. While antibiotics remain the primary treatment, antimicrobial resistance is a growing global concern, necessitating effective non-antibiotic alternatives.</p><p><strong>Objectives: </strong>This study determines the safety and efficacy of herbal formulation compared to nitrofurantoin in treating uncomplicated UTI and its impact on health-related quality of life (HRQoL) in women.</p><p><strong>Methodology: </strong>A randomized, standard-controlled study was conducted involving 66 women diagnosed with uUTI. Participants were randomly assigned to either the Unani Herbal Formulations group (UHF) or the nitrofurantoin group (NG). The UHF group (n=33) received a Unani herbal formulation (3.5 g powder of Cucumis sativus L., Lagenaria siceraria, Portulaca oleracea L., Malva sylvestris L., and Adiantum capillus-veneris L.) along with 25 ml of Viola odorata L. syrup, administered twice daily for 8 days. The NG (n=33) received nitrofurantoin (100 mg) twice daily for 7 days. The primary outcome was the Urinary Tract Infection Symptom Assessment (UTISA) questionnaire. The secondary outcomes were symptom severity, urine dipstick test, urine culture and sensitivity, SF-12 HRQoL survey, and safety evaluation. Standardization, in vitro, and phytochemical analyses of the herbal formulation were also conducted.</p><p><strong>Results: </strong>UTISA scores significantly improved within both groups (p<0.001). The UTISA total score from 14.21 ± 3.43 and 14.18 ± 3.36 was reduced to 3.12 ± 4.65 and 1.61 ± 3.10 in the UHF and NG, respectively, on the 9th day. On the 9th day, 81.81% (UHF) and 87.87% (NG) had negative cultures. HRQoL scores showed significant within-group improvements (p < 0.001), with no significant difference between groups (p > 0.05). No adverse effects were reported. HPLC analysis confirmed the presence of Luteolin, a bioactive antimicrobial metabolite.</p><p><strong>Conclusion: </strong>The herbal formulations were as effective as nitrofurantoin in treating bacterial uUTIs, with no adverse effects and enhanced HRQoL. The presence of Luteolin supports its antimicrobial potential, offering a favourable non-antibiotic alternative for UTI management.</p><p><strong>Trial registration: </strong>The research project is registered at the Clinical Trial Registry of India, ICMR with No: CTRI/2021/09/036138 dated 01/09/2021. The protocol can be retrieved from CTRI.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Randomized Comparative Study of Luteolin-Based Herbal Unani Formulations versus Nitrofurantoin in Women with Uncomplicated Urinary Tract Infections.\",\"authors\":\"Arshiya Sultana, Khaleequr Rahman, Saiyad Shah Alam\",\"doi\":\"10.2174/0113816128389673250415101004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Urinary tract infection (UTI) is a common infection, particularly among reproductive- age and elderly women. While antibiotics remain the primary treatment, antimicrobial resistance is a growing global concern, necessitating effective non-antibiotic alternatives.</p><p><strong>Objectives: </strong>This study determines the safety and efficacy of herbal formulation compared to nitrofurantoin in treating uncomplicated UTI and its impact on health-related quality of life (HRQoL) in women.</p><p><strong>Methodology: </strong>A randomized, standard-controlled study was conducted involving 66 women diagnosed with uUTI. Participants were randomly assigned to either the Unani Herbal Formulations group (UHF) or the nitrofurantoin group (NG). The UHF group (n=33) received a Unani herbal formulation (3.5 g powder of Cucumis sativus L., Lagenaria siceraria, Portulaca oleracea L., Malva sylvestris L., and Adiantum capillus-veneris L.) along with 25 ml of Viola odorata L. syrup, administered twice daily for 8 days. The NG (n=33) received nitrofurantoin (100 mg) twice daily for 7 days. The primary outcome was the Urinary Tract Infection Symptom Assessment (UTISA) questionnaire. The secondary outcomes were symptom severity, urine dipstick test, urine culture and sensitivity, SF-12 HRQoL survey, and safety evaluation. Standardization, in vitro, and phytochemical analyses of the herbal formulation were also conducted.</p><p><strong>Results: </strong>UTISA scores significantly improved within both groups (p<0.001). The UTISA total score from 14.21 ± 3.43 and 14.18 ± 3.36 was reduced to 3.12 ± 4.65 and 1.61 ± 3.10 in the UHF and NG, respectively, on the 9th day. On the 9th day, 81.81% (UHF) and 87.87% (NG) had negative cultures. HRQoL scores showed significant within-group improvements (p < 0.001), with no significant difference between groups (p > 0.05). No adverse effects were reported. HPLC analysis confirmed the presence of Luteolin, a bioactive antimicrobial metabolite.</p><p><strong>Conclusion: </strong>The herbal formulations were as effective as nitrofurantoin in treating bacterial uUTIs, with no adverse effects and enhanced HRQoL. The presence of Luteolin supports its antimicrobial potential, offering a favourable non-antibiotic alternative for UTI management.</p><p><strong>Trial registration: </strong>The research project is registered at the Clinical Trial Registry of India, ICMR with No: CTRI/2021/09/036138 dated 01/09/2021. The protocol can be retrieved from CTRI.</p>\",\"PeriodicalId\":10845,\"journal\":{\"name\":\"Current pharmaceutical design\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pharmaceutical design\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113816128389673250415101004\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128389673250415101004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:尿路感染(UTI)是一种常见的感染,特别是在育龄和老年妇女中。虽然抗生素仍然是主要的治疗方法,但抗菌素耐药性是一个日益受到全球关注的问题,需要有效的非抗生素替代品。目的:本研究确定与呋喃妥因相比,中草药制剂治疗无并发症UTI的安全性和有效性及其对女性健康相关生活质量(HRQoL)的影响。方法:对66名诊断为uUTI的女性进行了一项随机、标准对照研究。参与者被随机分配到Unani草药制剂组(UHF)或呋喃妥因组(NG)。UHF组(n=33)给予Unani草药配方(黄瓜、木槿花、马蹄苋、木槿花、金针花粉末3.5 g)和25 ml堇菜糖浆,每天2次,连用8天。NG组(n=33)给予呋喃妥因100 mg,每日2次,连用7天。主要结果是尿路感染症状评估(UTISA)问卷。次要结局为症状严重程度、尿试纸试验、尿培养及敏感性、SF-12 HRQoL调查、安全性评价。对该制剂进行了标准化、体外和植物化学分析。结果:两组患者UTISA评分均有显著提高(p < 0.05)。无不良反应报告。HPLC分析证实木犀草素是一种具有生物活性的抗菌代谢物。结论:中药制剂治疗细菌性utis的疗效与呋喃妥英相同,且无不良反应,可提高HRQoL。木犀草素的存在支持其抗菌潜力,为尿路感染管理提供了有利的非抗生素替代方案。试验注册:该研究项目在印度临床试验注册中心注册,ICMR,编号:CTRI/2021/09/036138,日期为2021年9月1日。该协议可以从CTRI中检索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Randomized Comparative Study of Luteolin-Based Herbal Unani Formulations versus Nitrofurantoin in Women with Uncomplicated Urinary Tract Infections.

Background: Urinary tract infection (UTI) is a common infection, particularly among reproductive- age and elderly women. While antibiotics remain the primary treatment, antimicrobial resistance is a growing global concern, necessitating effective non-antibiotic alternatives.

Objectives: This study determines the safety and efficacy of herbal formulation compared to nitrofurantoin in treating uncomplicated UTI and its impact on health-related quality of life (HRQoL) in women.

Methodology: A randomized, standard-controlled study was conducted involving 66 women diagnosed with uUTI. Participants were randomly assigned to either the Unani Herbal Formulations group (UHF) or the nitrofurantoin group (NG). The UHF group (n=33) received a Unani herbal formulation (3.5 g powder of Cucumis sativus L., Lagenaria siceraria, Portulaca oleracea L., Malva sylvestris L., and Adiantum capillus-veneris L.) along with 25 ml of Viola odorata L. syrup, administered twice daily for 8 days. The NG (n=33) received nitrofurantoin (100 mg) twice daily for 7 days. The primary outcome was the Urinary Tract Infection Symptom Assessment (UTISA) questionnaire. The secondary outcomes were symptom severity, urine dipstick test, urine culture and sensitivity, SF-12 HRQoL survey, and safety evaluation. Standardization, in vitro, and phytochemical analyses of the herbal formulation were also conducted.

Results: UTISA scores significantly improved within both groups (p<0.001). The UTISA total score from 14.21 ± 3.43 and 14.18 ± 3.36 was reduced to 3.12 ± 4.65 and 1.61 ± 3.10 in the UHF and NG, respectively, on the 9th day. On the 9th day, 81.81% (UHF) and 87.87% (NG) had negative cultures. HRQoL scores showed significant within-group improvements (p < 0.001), with no significant difference between groups (p > 0.05). No adverse effects were reported. HPLC analysis confirmed the presence of Luteolin, a bioactive antimicrobial metabolite.

Conclusion: The herbal formulations were as effective as nitrofurantoin in treating bacterial uUTIs, with no adverse effects and enhanced HRQoL. The presence of Luteolin supports its antimicrobial potential, offering a favourable non-antibiotic alternative for UTI management.

Trial registration: The research project is registered at the Clinical Trial Registry of India, ICMR with No: CTRI/2021/09/036138 dated 01/09/2021. The protocol can be retrieved from CTRI.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信